Alzheimer's Disease
Cross-source consensus on Alzheimer's Disease from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Benefits
Risks & contraindications
Background
Highlighted claims
- The Alzheimer’s simulation perturbed ceramidase activity, sphingosine kinase dynamics, ceramide kinase dynamics, CERT-mediated ceramide transport, and de novo ceramide inflow. — Computational model of sphingolipids metabolism: a case study of Alzheimer's disease
- After additional modifications, the Alzheimer’s scenario reproduced reported patterns of ceramide accumulation, sphingosine accumulation after an initial drop, and decreased S1P species. — Computational model of sphingolipids metabolism: a case study of Alzheimer's disease
- Prior Alzheimer’s-related sphingolipid changes include ceramide accumulation in endoplasmic reticulum and lysosome, cytoplasmic sphingosine accumulation, and reduced cytoplasmic S1P and C1P. — Computational model of sphingolipids metabolism: a case study of Alzheimer's disease
- Initial Alzheimer’s simulations based only on prior pathway literature produced biologically implausible sphingomyelin and glycosphingolipid accumulation. — Computational model of sphingolipids metabolism: a case study of Alzheimer's disease
- The model predicted that reduced CERT-independent ceramide transport to Golgi, increased sphingomyelinase activity, and minor sphingomyelin transport changes were needed in the Alzheimer’s scenario. — Computational model of sphingolipids metabolism: a case study of Alzheimer's disease